Stem (NYSE:STEM) Stock, Quote.Headers.trade-ideas

Stem

Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on innovative technology services that transform the way energy is distributed and consumed.

Wall Street

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

GTHX

PETQ

STEM

TLIS

UPST

XPON

Dow Tumbles Over 200 Points; CVS Health Cuts Profit Forecast

oil ai

Crude Oil Jumps Over 3%; Upstart Shares Spike Higher

Fortinet_logo

Pre-Market Outlook

Movers

CRVS

CYRX

DZSI

FTNT

LITM

LUMN

MYND

NVRO

PRCH

SCPX

SWIM

VBIV

XAIR

ZCMD

Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Stem Inc

STEM CELL COIN

STEM CELL AUTHORITY LTD by Stem Cell Authority, Ltd.

Stem Cell Authority Ltd

Stem Holdings Inc

StemGen Inc

STEMCELL HLDGS INC by Stemcell Hldgs Inc.

Stemcell Holdings Inc

STEMSATION INTL INC by Stemsation International, Inc.

Stemsation International Inc

Stemtech Corp

David Buzby, Executive Chair of the Company&#39;s Board of Directors, has been appointed interim CEO, effective immediately. Mr. Buzby will continue to serve in his current role as Executive Chair of the Board of Directors. The Company is concluding its previously announced strategy review and expects to publicly announce the outcome of its review in the coming weeks. The identification of a new permanent CEO is critical to the Company&#39;s successful execution of its new strategy.

Stem Names David Buzby As Interim CEO Following John Carrington's Departure

Stem Receives NYSE Notice For Falling Below $1.00 Per Share Minimum; Company Plans To Cure Deficiency Within Six-Month Period To Maintain Listing

Susquehanna analyst Biju Perincheril downgrades Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) from Positive to Neutral and lowers the price target from $2 to $0.5.

Downgrades

Price Target

Analyst Ratings

Susquehanna Downgrades Stem to Neutral, Lowers Price Target to $0.5

Goldman Sachs analyst Brian Lee maintains Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) with a Neutral and lowers the price target from $1.4 to $0.75.

Goldman Sachs Maintains Neutral on Stem, Lowers Price Target to $0.75

UBS analyst Jon Windham maintains Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) with a Buy and lowers the price target from $2.5 to $1.

UBS Maintains Buy on Stem, Lowers Price Target to $1

TD Cowen analyst Thomas Boyes downgrades Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) from Buy to Hold and lowers the price target from $4 to $1.

TD Cowen Downgrades Stem to Hold, Lowers Price Target to $1

U.S. stocks turned lower toward the end of trading, with the Dow Jones index dipping more than 200 points on Wednesday.
The Dow traded down 0.55% to 38,784.80 while the NASDAQ fell 0.67% to 16,257.11. The S&amp;P 500 also fell, dropping, 0.45% to 5,216.41.
Leading and Lagging Sectors Energy shares climbed by 1.7% on Wednesday.
In trading on Wednesday, health care shares fell by 0.6%.
Top Headline CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) shares fell over 1% on Wednesday fell after the company reported mixed second-quarter earnings and cut annual profit guidance.
The company reported second-quarter sales of $91.23 billion, missing the consensus of $91.51 billion. Adjusted EPS of $1.83 decreased from $2.21 in the prior year, beating the consensus of $1.73.
CVS Health revised its adjusted EPS guidance to $6.40-$6.65 from at least $7.00 versus consensus of $6.98. CVS Health also revised its full-year 2024 cash flow from operations guidance to approximately $9.0 billion from at least $10.5 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) shares shot up 48% to $35.26 after the company reported better-than-expected second-quarter financial results and issued third-quarter revenue guidance above estimates on Tuesday.</li>
<li>Shares of G1 Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTHX#NASDAQ">GTHX</a>) got a boost, surging 66% to $7.05 after the company announced it will be acquired by Pharmacosmos Group in an all-cash transaction valued at $405 million.</li>
<li>PetIQ, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PETQ#NASDAQ">PETQ</a>) shares were also up, gaining 48% to $30.41 after the company reported better-than-expected second-quarter adjusted earnings results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Stem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) shares dropped 42% to $0.5791 after the company reported mixed second-quarter financial results.</li>
<li>Shares of Expion360 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) were down 69% to $0.0810 after the company reported the pricing of $10 million underwritten public offering.</li>
<li>Talis Biomedical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLIS#NASDAQ">TLIS</a>) was down, falling 49% to $4.63. The company announced board restructuring, appointed new directors and updated investors on potential bankruptcy proceedings.</li>
</ul>
Commodities In commodity news, oil traded up 2.7% to $75.18 while gold traded up 0.1% at $2,433.40.
Silver traded down 1.2% to $26.88 on Wednesday, while copper fell 2.1% to $3.9440.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 1.54%, Germany's DAX rose 1.50% and France's CAC 40 climbed 1.91%. Spain's IBEX 35 Index gained 2.01%, while London's FTSE 100 rose 1.75%.
Asia Pacific Markets
Asian markets closed higher on Wednesday, with Japan's Nikkei 225 jumping 1.19%, Hong Kong's Hang Seng Index gaining 1.38%, China's Shanghai Composite Index rising 0.09% and S&amp;P BSE Sensex jumping 1.11%.
Economics
<ul>
<li>The Manheim Used Vehicle Value Index rose 2.8% month-over-month for July.</li>
<li>Mortgage applications rose by 6.9% from the prior week in the period ending August 2.</li>
<li>The EIA said crude oil inventories in the U.S. declined by 3.728 million barrels in the week ended Aug. 2, compared to market estimates of a 0.4 million-barrel decline.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40217393/top-3-real-estate-stocks-that-may-explode-this-quarter">Top 3 Real Estate Stocks That May Explode This Quarter</a></li>
</ul>

WIIM

Stem shares are trading lower after the company reported mixed Q2 financial results and cut its FY24 revenue guidance below estimates.

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 250 points on Wednesday.
The Dow traded up 0.95% to 39,367.42 while the NASDAQ rose 1.52% to 16,616.10. The S&amp;P 500 also rose, gaining, 1.33% to 5,309.90.
Leading and Lagging Sectors Energy shares climbed by 2% on Wednesday.
In trading on Wednesday, health care shares rose by just 0.1%.
Top Headline The EIA said crude oil inventories in the U.S. declined by 3.728 million barrels in the week ended Aug. 2, compared to market estimates of a 0.4 million barrel decline.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) shares shot up 50% to $35.77 after the company reported better-than-expected second-quarter financial results and issued third-quarter revenue guidance above estimates on Tuesday.</li>
<li>Shares of G1 Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTHX#NASDAQ">GTHX</a>) got a boost, surging 66% to $7.07 after the company announced it will be acquired by Pharmacosmos Group in an all-cash transaction valued at $405 million.</li>
<li>PetIQ, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PETQ#NASDAQ">PETQ</a>) shares were also up, gaining 48% to $30.44 after the company reported better-than-expected second-quarter adjusted earnings results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Stem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) shares dropped 41% to $0.5844 after the company reported mixed second-quarter financial results.</li>
<li>Shares of Expion360 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) were down 68% to $0.0827 after the company reported the pricing of $10 million underwritten public offering.</li>
<li>Talis Biomedical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLIS#NASDAQ">TLIS</a>) was down, falling 49% to $4.58. The company announced board restructuring, appointed new directors and updated investors on potential bankruptcy proceedings.</li>
</ul>
Commodities In commodity news, oil traded up 3.5% to $75.76 while gold traded up 0.3% at $2,437.90.
Silver traded down 0.4% to $27.095 on Wednesday, while copper fell 1.5% to $3.9655.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 1.55%, Germany's DAX rose 1.46% and France's CAC 40 climbed 1.87%. Spain's IBEX 35 Index gained 2.13%, while London's FTSE 100 rose 1.71%.
Asia Pacific Markets
Asian markets closed higher on Wednesday, with Japan's Nikkei 225 jumping 1.19%, Hong Kong's Hang Seng Index gaining 1.38%, China's Shanghai Composite Index rising 0.09% and S&amp;P BSE Sensex jumping 1.11%.
Economics
<ul>
<li>The Manheim Used Vehicle Value Index rose 2.8% month-over-month for July.</li>
<li>Mortgage applications rose by 6.9% from the prior week in the period ending August 2.</li>
<li>The EIA said crude oil inventories in the U.S. declined by 3.728 million barrels in the week ended Aug. 2, compared to market estimates of a 0.4 million barrel decline.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40217393/top-3-real-estate-stocks-that-may-explode-this-quarter">Top 3 Real Estate Stocks That May Explode This Quarter</a></li>
</ul>

Evercore ISI Group analyst James West maintains Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) with a Outperform and lowers the price target from $9 to $5.

Evercore ISI Group Maintains Outperform on Stem, Lowers Price Target to $5

Shares of Fortinet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results and<a href="https://www.benzinga.com/news/earnings/24/08/40203474/fortinet-q2-earnings-revenue-beat-eps-beat-strong-guidance-and-more"> issued guidance above estimates.</a>
Fortinet's second-quarter revenue increased 11% year-over-year to $1.43 billion, beating consensus estimates of $1.403 billion. The cybersecurity company reported second-quarter adjusted earnings of 57 cents per share, beating analyst estimates of 41 cents per share.
Fortinet shares jumped 17% to $65.29 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Richtech Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) rose 68.1% to $0.6220 in today's pre-market trading after dipping around 74% on Tuesday.</li>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) gained 43% to $7.15 in pre-market trading after the company reported better-than-expected second-quarter revenue results.</li>
<li>Zhongchao Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCMD#NASDAQ">ZCMD</a>) gained 34.2% to $1.65 in pre-market trading.</li>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) jumped 24% to $29.60 in pre-market trading after the company reported better-than-expected second-quarter financial results and issued third-quarter revenue guidance above estimates.</li>
<li>Latham Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) shares gained 20.6% to $3.75 in pre-market trading after the company reported better-than-expected second-quarter financial results and raised its FY24 revenue guidance above estimates. Additionally, the company announced an acquisition of Coverstar Central.</li>
<li>Mynd.ai, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYND#NYSE">MYND</a>) shares rose 15.9% to $2.55 in pre-market trading after falling around 7% on Tuesday.</li>
<li>Beyond Air, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares rose 14.3% to $0.5770 in pre-market trading after the company reported better-than-expected quarterly EPS results.</li>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) gained 12.8% to $0.5756 in pre-market trading after jumping around 13% on Tuesday.</li>
<li>Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) shares gained 10% to $3.30 in pre-market trading after the company reported a narrower-than-expected quarterly loss.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Scorpius Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#NYSE">SCPX</a>) shares dipped 77% to $1.30 in pre-market trading after gaining 19% on Tuesday. Scorpius announced that it has surpassed $100 million in near-term business development opportunities across government and commercial sectors.</li>
<li>Talis Biomedical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLIS#NASDAQ">TLIS</a>) shares declined 52.7% to $4.25 in pre-market trading after the company initiated a board restructuring.</li>
<li>Porch Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) declined 38.2% to $1.07 in pre-market trading after reporting weak quarterly results.</li>
<li>Stem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) shares declined 37.1% to $0.6274 in pre-market trading after the company reported mixed second-quarter financial results.</li>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares fell 36.2% to $6.27 in pre-market trading after posting a loss for the second quarter.</li>
<li>DZS Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DZSI#NASDAQ">DZSI</a>) fell 36.2% to $0.66 pre-market trading after the company announced it received a delisting notice from the Nasdaq.</li>
<li>VBI Vaccines Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBIV#NASDAQ">VBIV</a>) fell 32.2% to $0.09 in today's pre-market trading after jumping 111% on Tuesday.</li>
<li>Nevro Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) shares fell 31.1% to $5.99 in pre-market trading after the company reported worse-than-expected second-quarter sales results.</li>
<li>Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) fell 24.5% to $2.90 in pre-market trading after declining around 11% on Tuesday.</li>
<li>Cryoport, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) shares fell 23.5% to $5.95 in pre-market trading after posting weak quarterly sales.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40194186/top-4-materials-stocks-which-could-rescue-your-portfolio-this-month">Top 4 Materials Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>

Outlook
The Company is updating its full year 2024 guidance ranges as follows ($ millions, unless otherwise noted):
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Previous</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Updated</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$567 - $667</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$200 - $270</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP Gross Margin (%)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">15% - 20%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">25% - 30%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$5 - $20</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">($30) - ($20)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Bookings</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$1,500 - $2,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$600 - $1,100</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">CARR (year-end)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$115 - $130</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$100 - $110</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating Cash Flow</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Greater than $50</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Greater than $15</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Guidance

Stem Sees FY24 Revenue $200M-$270M Vs $567M-$667M Prior, $599M Estimate

Stem shares are trading lower after the company reported mixed Q2 financial results.

Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.23) by 4.35 percent. The company reported quarterly sales of $33.999 million which missed the analyst consensus estimate of $64.946 million by 47.65 percent. This is a 63.42 percent decrease over sales of $92.946 million the same period last year.

Earnings Beats

Earnings Misses

Stem Q2 2024 Adj. EPS $(0.22) Beats $(0.23) Estimate, Sales $33.999M Miss $64.946M Estimate

Doran Hole Named Chief Financial Officer and Executive Vice President
David Buzby Named Executive Chair of the Board; Laura D'Andrea Tyson Named Lead Independent Director of the Board
Company Initiates Strategic Review of Business
Company Separately Reports Second Quarter 2024 Earnings; Conference Call at 5:00 p.m. ET
Stem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>), a global leader in artificial intelligence (AI)-driven clean energy software and services, today announced the following leadership changes to support the execution of the Company's strategic priorities.
Doran Hole has been appointed Chief Financial Officer (CFO) and Executive Vice President (EVP), effective September 2, 2024. In addition to the CFO role, Mr. Hole will oversee the Company's software and services group, focused on delivering high quality customer relevant software and service solutions, including the recently announced Athena&#xAE; PowerBidder&#x2122; Pro product. Mr. Hole succeeds Bill Bush, who is stepping down as CFO, effective September 2, 2024. Mr. Bush will continue to lead the Company's public power and large scale FTM projects, as well as the supply chain team. Mr. Bush's stepping down as CFO is unrelated to the Company's financial or operating results or any disagreement with the Company regarding its financial, operational, accounting or reporting policies or practices.
Mr. Hole is an executive with more than 25 years of global finance and management experience, providing leadership in strategy and operational efficiency in the clean technology industry. He most recently served as EVP and CFO of Ameresco, where he led the Company's financial strategy, capital management as well as strategic digitization efforts across the organization. Prior to that, he served as CEO for North America, and Group Vice President - Strategy, at ReneSola, where he played a key role in the Company's capital markets strategy, North American operations and finance activities.

Management

Stem Appoints Doran Hole As Chief Financial Officer; David Buzby Named Executive Chair Of The Board; Company Initiates Strategic Review Of Business

Shares of SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) rose sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/news/earnings/24/07/39895236/sap-stock-is-up-after-q2-results-heres-a-look-at-the-details">second-quarter financial results.</a>
SAP reported quarterly earnings of 82 cents per share which missed the analyst consensus estimate of $1.19 per share. Quarterly sales came in at $8.92 billion which missed the analyst consensus estimate of $8.96 billion, representing an 8.81% increase over sales from the same period last year, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
SAP shares gained 5.9% to $212.34 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Nature&#8217;s Miracle Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) rose 183.4% to $0.9779 in pre-market trading after falling 13% on Monday.</li>
<li>Volato Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NYSE">SOAR</a>) gained 140.5% to $1.15 in pre-market trading after jumping around 20% on Monday.</li>
<li>Frequency Electronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEIM#NASDAQ">FEIM</a>) shares climbed 32% to $13.33 in pre-market trading following fourth-quarter earnings. Also, the company declared a $1.00 special cash dividend.</li>
<li>MSP Recovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) gained 24.6% to $0.6319 in pre-market trading after the company announced a settlement with another group of affiliated P&amp;C insurers.</li>
<li>Mammoth Energy Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TUSK#NASDAQ">TUSK</a>) shares gained 23.1% to $4.31 in pre-market trading after the company announced its subsidiary, Cobra Acquisitions, entered into a release and settlement agreement with the Puerto Rico Electric Power Authority.</li>
<li>MAIA Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAIA#NASDAQ">MAIA</a>) gained 22.9% to $4.61 in pre-market trading after reporting Phase 2 results for lung cancer treatment THIO.</li>
<li>Professional Diversity Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) shares gained 20.2% to $0.59 in pre-market trading.</li>
<li>New Horizon Aircraft Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>) shares gained 13.5% to $0.6105 in pre-market trading after falling over 8% on Monday.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares surged 12.5% to $8.50 in pre-market trading. Mesoblast recently started enrollment in Phase 3 trial of Rexlemestrocel-L for chronic low back pain.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>TransCode Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares fell 57.2% to $0.3395 in pre-market trading. TransCode Therapeutics priced its $3 million public offering of 10 million common shares at $0.30 per share.</li>
<li>MIRA Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) shares fell 30.3% to $3.49 in pre-market trading. MIRA Pharmaceuticals shares jumped 627% on Monday after the company announced new preclinical study results for its novel oral ketamine analog, Ketamir-2.</li>
<li>CareMax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares fell 25.3% to $3.87 in pre-market trading after surging 228% on Monday.</li>
<li>Nukkleus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) shares declined 21.5% to $0.3910 in pre-market trading after gaining over 55% on Monday.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares fell 17.5% to $0.41 in pre-market trading after declining around 7% on Monday.</li>
<li>Castellum, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTM#NYSE">CTM</a>) fell 15% to $0.17 in pre-market trading. Castellum recently announced a new strategic alliance with Krilla Kaleiwahea.</li>
<li>Medpace Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) shares declined 12.6% to $382.00 in pre-market trading after the company reported mixed second-quarter financial results and narrowed its FY24 revenue guidance with its midpoint below estimates.</li>
<li>Netcapital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCPL#NASDAQ">NCPL</a>) fell 11.8% to $0.0989 in pre-market trading after gaining around 8% on Monday.</li>
<li>Stem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) shares dipped 11.4% to $1.17 in pre-market trading after gaining 7% on Monday.</li>
<li>NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) shares fell 9.1% to $258.03 in pre-market trading following mixed second-quarter earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39881526/wall-streets-most-accurate-analysts-say-hold-these-3-utilities-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Say Hold These 3 Utilities Stocks With Over 5% Dividend Yields</a></li>
</ul>

CMAX

FEIM

HOVR

IPDN

LIFW

MAIA

MEDP

MESO

MIRA

NCPL

NMHI

NUKK

NXPI

RNAZ

SOAR

TUSK

XCUR

Why SAP Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

In the latest quarter, 5 analysts provided ratings for Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Stem and provided 12-month price targets. The average target is $3.47, accompanied by a high estimate of $9.00 and a low estimate of $1.85. A negative shift in sentiment is evident as analysts have decreased the average price target by 31.96%. 
<img src="https://www.benzinga.com/files/images/story/2024/1721059254_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Stem among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$2.00</td>
<td>$2.50</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$2.50</td>
<td>$5.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2.00</td>
<td>$2.50</td>
</tr>
<tr>
<td>James West</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$9.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$1.85</td>
<td>$2.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Stem. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Stem compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Stem's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Stem's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STEM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Stem analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Stem's Background</h2>
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on innovative technology services that transform the way energy is distributed and consumed.
<h3>Stem: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Stem's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -62.21%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Stem's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -283.9%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Stem's ROE excels beyond industry benchmarks, reaching -18.13%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Stem's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -5.47%, the company showcases efficient use of assets and strong financial health.
Debt Management: Stem's debt-to-equity ratio is below the industry average at 1.44, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Stem Stock

Susquehanna analyst Biju Perincheril maintains Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) with a Positive and lowers the price target from $2.5 to $2.

Susquehanna Maintains Positive on Stem, Lowers Price Target to $2

Project strengthens Stem's growing foothold in the public power sector; helps Sulphur Springs Valley Electric Co-op deliver reliable clean power to its members
Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>), a global leader in AI-driven clean energy solutions and services, and Arizona Electric Power Cooperative (AEPCO), a not-for-profit, member-owned electric generation and transmission (G&amp;T) cooperative, in partnership with Prometheus Power (Prometheus), a national renewable energy developer, today announced the successful deployment of a co-located storage and solar project to help deliver clean, reliable power to its distribution co-ops and public power members.

Stem, AEPCO Partner With Prometheus Power To Deploy Storage And Solar Project For Arizona Member Co-op

UBS analyst Jon Windham maintains Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) with a Buy and lowers the price target from $5 to $2.5.

UBS Maintains Buy on Stem, Lowers Price Target to $2.5

Roth MKM analyst Justin Clare maintained a Hold rating on Stem Inc (STEM – Research Report) today and set a price target of $0.90. The company's sh...

Roth MKM Reaffirms Their Hold Rating on Stem Inc (STEM)

Stem sinks to all-time low after posting big Q2 miss, reducing revenue forecast

Goldman Sachs analyst Brian K. Lee has maintained their neutral stance on STEM stock, giving a Hold rating yesterday. Brian K. Lee's rating is base...

Hold Rating Maintained for Stem Inc. Amid Financial Challenges and Strategic Review

Executive reshuffles: Uranium Energy, Nutrien and Logitech International Companies in focus

Solar, clean energy stocks surge as Powell points to imminent rate cuts

Stem Inc (STEM) has issued an announcement. Stem, Inc. has been notified by the NYSE that its stock price has dipped below the required $1.00 avera...

Stem Inc. Faces NYSE Delisting Risk, Plans Compliance

Stem receives continued listing standard notice from NYSE

Stem names interim CEO as John Carrington steps down

Stem Inc ( ($STEM) ) just unveiled an announcement. Stem, Inc. has undergone a significant leadership transformation with the resignation of CEO Jo...

Stem Inc. Undergoes Leadership Shift with Interim CEO

Solar, clean energy stocks rally ahead of Fed decision on interest rates

ACES

ARRY

BLDP

CLNE

CNRG

CSIQ

ENPH

ERTH

FCEL

FLNC

FSLR

GPRE

ICLN

ITCI

LOGI

MAXN

NOVA

PLUG

QCLN

SEDG

SHLS

SMOG

TPIC

Press Releases

Stem Announces Appointment of AI Industry Leader as New Independent Director

Stem Announces First Quarter 2024 Results

Stem Announces PowerTrack™ APM for Comprehensive Solar and Storage Energy Portfolio Management

Stem and AEPCO Deploy Storage and Solar Project for Arizona Member Co-Op

Stem Announces Second Quarter 2024 Earnings Results Conference Call

Stem Announces Second Quarter 2024 Results

Stem Announces Leadership Changes

Stem, Inc. Receives Continued Listing Standard Notice from NYSE

Marathon Capital Hires James Fitzgerald as Head of Institutional Sales

Stem Announces CEO Transition

AMPS

CHPT

CWEN

EVGO

GNRC

HASI

MEMC

OPAL

SPWRQ

Amprius Technologies

Asia Pacific Wire & Cable Corporation Limited - Common shares, Par value .01 per share

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Stem

Stem (STEM) Forecast

Stem (NYSE:STEM) Stock, Quote.Headers.trade-ideas